Identification of Novel Epigenetic Markers of Prostate Cancer by NotI-Microarray Analysis

Disease Markers ◽

10.1155/2015/241301 ◽

2015 ◽

Vol 2015 ◽

pp. 1-13 ◽

Cited By ~ 22

Author(s):

Alexey A. Dmitriev ◽

Eugenia E. Rosenberg ◽

George S. Krasnov ◽

Ganna V. Gerashchenko ◽

Vasily V. Gordiyuk ◽

...

Keyword(s):

Prostate Cancer ◽

Enrichment Analysis ◽

Cancer Diagnostics ◽

Epigenetic Alterations ◽

Prostate Tumors ◽

Diagnostic Biomarkers ◽

Functional Relations ◽

Novel Biomarkers ◽

Aggressive Tumors

A significant need for reliable and accurate cancer diagnostics and prognosis compels the search for novel biomarkers that would be able to discriminate between indolent and aggressive tumors at the early stages of disease. The aim of this work was identification of potential diagnostic biomarkers for characterization of different types of prostate tumors. NotI-microarrays with 180 clones associated with chromosome 3 genes/loci were applied to determine genetic and epigenetic alterations in 33 prostate tumors. For 88 clones, aberrations were detected in more than 10% of tumors. The major types of alterations were DNA methylation and/or deletions. Frequent methylation of the discovered loci was confirmed by bisulfite sequencing on selective sampling of genes:FGF12,GATA2, andLMCD1. Three genes (BHLHE40,BCL6, andITGA9) were tested for expression level alterations using qPCR, and downregulation associated with hypermethylation was shown in the majority of tumors. Based on these data, we proposed the set of potential biomarkers for detection of prostate cancer and discrimination between prostate tumors with different malignancy and aggressiveness:BHLHE40,FOXP1,LOC285205,ITGA9,CTDSPL,FGF12,LOC440944/SETD5,VHL,CLCN2,OSBPL10/ZNF860,LMCD1,FAM19A4,CAND2,MAP4,KY, andLRRC58. Moreover, we probabilistically estimated putative functional relations between the genes within each set using the network enrichment analysis.

Download Full-text

Isolation and characterization of urine exosomes for using as diagnostic biomarkers in prostate cancer

Clinica Chimica Acta ◽

10.1016/j.cca.2019.04.013 ◽

2019 ◽

Vol 493 ◽

pp. S3

Author(s):

A. Antón Cornejo ◽

M. Herraiz López ◽

Á. Sanchís Bonet ◽

J. Recio ◽

A.M. Bajo Chueca ◽

...

Keyword(s):

Prostate Cancer ◽

Diagnostic Biomarkers ◽

Isolation And Characterization ◽

Urine Exosomes

Download Full-text

Isolation and characterization of urine exosomes for using as diagnostic biomarkers in Prostate Cancer

European Urology Supplements ◽

10.1016/s1569-9056(18)33770-9 ◽

2018 ◽

Vol 17 (14) ◽

pp. e2913-e2914

Author(s):

A. Sanchis-Bonet ◽

J. Recio ◽

L. Ortega-Polledo ◽

L. Pulido-Fonseca ◽

L. Rodriguez-Elena ◽

...

Keyword(s):

Prostate Cancer ◽

Diagnostic Biomarkers ◽

Isolation And Characterization ◽

Urine Exosomes

Download Full-text

Down-regulation of miR-193b-3p and miR-376a-3p in Chronic Lymphocytic Leukemia

Research in Molecular Medicine ◽

10.18502/rmm.v6i3.4609 ◽

2019 ◽

Author(s):

Faezeh Namazi ◽

Nasrin Hadi ◽

Mansour Moghimi ◽

Amir Eshaghiyan ◽

Behnaz Nateghi

Keyword(s):

Chronic Lymphocytic Leukemia ◽

Tumor Suppressors ◽

Mononuclear Cells ◽

Control Strategies ◽

Enrichment Analysis ◽

Lymphocytic Leukemia ◽

Human Leukemia ◽

Peripheral Blood Mononuclear ◽

Diagnostic Biomarkers ◽

Novel Biomarkers

Background: Chronic lymphocytic leukemia (CLL) is the most common adult human leukemia. Studies revealed that microRNAs (miRNAs) can function as oncogenes or tumor suppressors in CLL and that the expression of miRNAs, such as miR-193b-3p and miR-376a-3p change in several diseases. We aimed to elucidate the changes in miR- 193b-3p and miR-376a-3p expression in CLL and determine their potential as diagnostic biomarkers for this disease. Materials and Methods: We investigated miR-193b-3p and miR-376a-3p expression by quantitative real-time PCR in peripheral blood mononuclear cells of 30 patients with CLL and 30 healthy individuals. Moreover, in silico molecular enrichment analysis was conducted on predicted and validated targets of miR-193b-3p and miR-376a-3p from the miRecords and miRTarBase databases. Results: The expression of miR-193b-3p and miR-376a-3p was significantly different between the two groups (P<0.0001 and P < 0.0001, respectively). Conclusion: Based on these findings, miR-193b-3p and miR-376a-3p could be novel biomarkers for the early diagnosis of CLL and could be used to design new CLL control strategies.

Download Full-text

Metabolic characterization and metabolism-score of tumor to predict the prognosis in prostate cancer

Scientific Reports ◽

10.1038/s41598-021-01140-6 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Yanlong Zhang ◽

Xuezhi Liang ◽

Liyun Zhang ◽

Dongwen Wang

Keyword(s):

Prostate Cancer ◽

Principal Component ◽

Enrichment Analysis ◽

Clinical Information ◽

Tumor Metabolism ◽

Activity Level ◽

Gene Set Enrichment Analysis ◽

Dna Mutation ◽

Metabolic Characteristics

AbstractTumor metabolism patterns have been reported to be associated with the prognosis of many cancers. However, the metabolic mechanisms underlying prostate cancer (PCa) remain unknown. This study aimed to explore the metabolic characteristics of PCa. First, we downloaded mRNA expression data and clinical information of PCa samples from multiple databases and quantified the metabolic pathway activity level using single-sample gene set enrichment analysis (ssGSEA). Through unsupervised clustering and principal component analyses, we explored metabolic characteristics and constructed a metabolic score for PCa. Then, we independently validated the prognostic value of our metabolic score and the nomogram based on the metabolic score in multiple databases. Next, we found the metabolic score to be closely related to the tumor microenvironment and DNA mutation using multi-omics data and ssGSEA. Finally, we found different features of drug sensitivity in PCa patients in the high/low metabolic score groups. In total, 1232 samples were analyzed in the present study. Overall, an improved understanding of tumor metabolism through the characterization of metabolic clusters and metabolic score may help clinicians predict prognosis and aid the development of more personalized anti-tumor therapeutic strategies for PCa.

Download Full-text